AEON Biopharma (AEON)

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
-$0.02 (-9.55%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0

Relative Strength Index (RSI)

- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.

- The RSI is calculated using the following formula:

RSI = 100 - (100 / (1 + RS))

Where RS is the ratio of the average gains to the average losses over a specified period.

- The default time period used is 14 days.

- RSI values range between 0 and 100.

RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)

RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)

RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.

About

Business overview of AEON Biopharma (AEON)
AEON Biopharma Inc is a clinical stage biopharmaceutical company focused on developing of its proprietary botulinum toxin complex ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, with an initial focus on the neurosciences market.

Key Insights

Critical company metrics and information

  • Share Price

    $0.19

  • Market Cap

    $7.60 Million

  • Total Outstanding Shares

    39.97 Million Shares

  • Total Employees

    5

  • Dividend

    No dividend

  • IPO Date

    July 24, 2023

  • SIC Description

    Pharmaceutical Preparations

  • Primary Exchange

    American Stock Exchange

  • Type

    Common Stock

  • Phone Number

    (949) 354-6499

  • Address

    5 park plaza, Irvine, CA, 92614

  • Homepage

    https://www.aeonbiopharma.com

Historical Stock Splits

Execution DateSplit Amount
No Historical Stock Splits

Cash Flow Statement

July 1, 2024 to September 30, 2024
MetricValue
Net Cash Flow, Continuing$0.00
Net Cash Flow From Operating Activities, Continuing$-2.96 Million
Net Cash Flow$0.00
Net Cash Flow From Investing Activities, Continuing$2.90 Million
Net Cash Flow From Operating Activities$-2.96 Million
Net Cash Flow From Financing Activities, Continuing$50,000.00

Income Statement

July 1, 2024 to September 30, 2024
MetricValue
Basic Earnings Per Share$-0.16
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic$0.00
Income/Loss From Continuing Operations Before Tax$-6.17 Million
Operating Income/Loss$-4.02 Million
Net Income/Loss$-6.17 Million
Research and Development$972,000.00

Balance Sheet

July 1, 2024 to September 30, 2024
MetricValue
Other Non-current Assets$1.38 Million
Noncurrent Liabilities$25.37 Million
Noncurrent Assets$1.63 Million
Current Assets$2.37 Million
Equity Attributable To Parent$-32.09 Million
Liabilities$36.09 Million

Historical Dividends

Announcement DatePayment DateRecord DateAmountFrequency
No historical dividends
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
Earnings CalendarNews ArticlesAbout UsPrivacy & Cookies Info

ⓒ 2025 Financhle. All Rights Reserved.